Amyloid-beta misfolding and GFAP predict risk of clinical Alzheimer's disease diagnosis within 17 years.

Autor:	Beyer L; Center for Protein Diagnostics (PRODI), Ruhr-University Bochum, Bochum, Germany.; Department of Biophysics, Ruhr-University Bochum, Bochum, Germany., Stocker H; Network Aging Research, Heidelberg University, Heidelberg, Germany.; Division of Clinical Epidemiology and Aging Research, German Cancer Research Center, Heidelberg, Germany., Rujescu D; Department of Psychiatry, Medical University of Vienna, Vienna, Austria., Holleczek B; Saarland Cancer Registry, Saarbrücken, Germany., Stockmann J; Center for Protein Diagnostics (PRODI), Ruhr-University Bochum, Bochum, Germany.; Department of Biophysics, Ruhr-University Bochum, Bochum, Germany., Nabers A; Center for Protein Diagnostics (PRODI), Ruhr-University Bochum, Bochum, Germany.; Department of Biophysics, Ruhr-University Bochum, Bochum, Germany., Brenner H; Network Aging Research, Heidelberg University, Heidelberg, Germany.; Division of Clinical Epidemiology and Aging Research, German Cancer Research Center, Heidelberg, Germany., Gerwert K; Center for Protein Diagnostics (PRODI), Ruhr-University Bochum, Bochum, Germany.; Department of Biophysics, Ruhr-University Bochum, Bochum, Germany.
Jazyk:	angličtina
Zdroj:	Alzheimer's & dementia : the journal of the Alzheimer's Association [Alzheimers Dement] 2023 Mar; Vol. 19 (3), pp. 1020-1028. Date of Electronic Publication: 2022 Jul 19.
DOI:	10.1002/alz.12745
Abstrakt:	Introduction: Blood-based biomarkers for Alzheimer's disease (AD) are urgently needed. Here, four plasma biomarkers were measured at baseline in a community-based cohort followed over 17 years, and the association with clinical AD risk was determined. Methods: Amyloid beta (Aβ) misfolding status as a structure-based biomarker as well as phosphorylated tau 181 (P-tau181), glial fibrillary acidic protein (GFAP), and neurofilament light (NfL) concentration levels were determined at baseline in heparin plasma from 68 participants who were diagnosed with AD and 240 controls without dementia diagnosis throughout follow-up. Results: Aβ misfolding exhibited high disease prediction accuracy of AD diagnosis within 17 years. Among the concentration markers, GFAP showed the best performance, followed by NfL and P-tau181. The combination of Aβ misfolding and GFAP increased the accuracy. Discussion: Aβ misfolding and GFAP showed a strong ability to predict clinical AD risk and may be important early AD risk markers. Aβ misfolding illustrated its potential as a prescreening tool for AD risk stratification in older adults. (© 2022 The Authors. Alzheimer's & Dementia published by Wiley Periodicals LLC on behalf of Alzheimer's Association.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu